Programme

This is a Provisional Conference Programme.

For further information on this event please contact us.

Welcome to Oxford & Opening Remarks
Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

SESSION 1:
OPENING PLENARY SESSION

Moderator: Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘A global perspective on universal influenza vaccines: What do we want and how will we use it?’
Christopher Chadwick, Martin Friede and Ann Moen
(World Health Organization, Geneva, Switzerland)

‘Scientific steps from the Spanish Influenza era have provided a firm foundation for both conventional and exploratory new influenza vaccines’
John S. Oxford and D. Gill
(Blizard Institute, Queen Mary College, London, UK)

‘Achieving better influenza vaccines: Implementation of NIAID’s strategic plan for universal influenza vaccine development’
Jennifer Gordon
(Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, HHS, Behesda, Maryland, USA)

‘What is a Universal Influenza Vaccine? Is it possible?’Rob Lambkin-Williams
(Virology Consult, London, UK)

Coffee Break & Poster Set-Up

SESSION 2:
UNIVERSAL VACCINES

Moderator: John Oxford
(Blizard Institute, Queen Mary College, London, UK)

‘The development of a new approach to influenza vaccination, from concept to efficacy testing’
Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘Development of a universal influenza vaccine technology landscape’ 
Julie Ostrowsky
(Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota, USA)

‘Development of universal influenza vaccines in Russia’
Yuri Vasiliev
(St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation)

Lunch Break & Posters

SESSION 3:
SUBTYPES/EPITOPES

Moderator: Anke L.W. Huckriede
(University Medical Center Groningen, Groningen, The Netherlands)

‘From subtype coverage to universal flu vaccines’
Shan Lu
(University of Massachusetts, Worcester, Massachusetts, USA)

‘Utilising epitopes of limited variability to produce a broadly neutralising influenza vaccine’
Craig P. Thompson1,2, Uri Obsolski1,2, Alex Fyfe1,2, Jose Lourenco1,2, Daniel O’Connor3, Teresa Lambe4, Christine Rollier3, Andrew Pollard3 and Sunetra Gupta1,2
(1 Department of Zoology, University of Oxford, Oxford, UK; 2 Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK; 3 Oxford Vaccine Group, Department of Paediatrics and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; 4 Jenner Institute, University of Oxford, Oxford, UK)

‘Targeting highly conserved influenza A and B virus epitopes with nanoparticle-based vaccines’
David F. Zeigler, Emily Gage and Christopher H. Clegg 
(TRIA Bioscience Corp, Seattle Washington, USA)

‘Permissive and preferential cell-lines for challenge agent and vaccine manufacture’Adrian Wildfire
(SGS, Camberley, UK)

Tea Break & Posters

SESSION 4:
STANDARDISATION/ASSAYS/CORRELATES OF PROTECTION

Moderator: To be confirmed

‘Standardisation of serology assays used in the evaluation of vaccines’
Othmar G. Engelhardt
(NIBSC, South Mimms, Potters Bar, UK)

‘Correlates of protection for influenza vaccines’
Emanuele Montomoli
(VisMederi SRl, Siena, Italy)

SESSION 5:
IMMUNITY – I

Moderator: Ted M. Ross
(University of Georgia, Athens, Georgia, USA)

‘The art of measuring influenza-specific immunity’
Anke L.W. Huckriede
(University Medical Center Groningen, Groningen, The Netherlands)

‘Human T cell immunology of influenza’
Teresa Lambe
(University of Oxford, Oxford, UK)

‘Novel immune correlates of protection against influenza infection’
Sean Tucker
(Vaxart Inc., South San Francisco, California, USA)

‘Immune response profile induced by live M2SR (M2-deficient single replication) influenza vaccine and protection against human challenge with a substantially drifted H3N2 strain’
Joseph Eiden1, Bram Volckaert2, Oleg Rudenko2, Ruth Ellis3, Roger Aitchison4, Renee Herber1, Lawrence Moulton5, Dan Hoft6, David Marshall1 and Pamuk Bilsel1
(1 FluGen, Inc., Madison, Wisconsin, USA; 2 SGS Life Sciences, Antwerp, Belgium; 3 Biologics Consulting, Alexandria, Virginia, USA; 4 North Rim Consulting, Denver, Colorado, USA; 5 Johns Hopkins University, Baltimore, Maryland, USA; 6 Saint Louis University, St. Louis, Missouri, USA)

Coffee Break & Posters

SESSION 6:
IMMUNITY

Moderator: Rob-Lambkin Williams
(Virology Consult, London, UK)

‘Vaccination with viral vectors expressing chimeric hemagglutinin, NP and M1 protects ferrets and mice against influenza virus challenge’Teresa Lambe1, M. McMahon2, G. Asthagiri Arunkumar2,3, W.C. Liu2,4, D. Stadlbauer2,5, A. Ioannou2, R.A. Albrecht2,4, V. Pavot1, M. Aramouni1, S.C. Gilbert1 and F. Krammer2
(1 The Jenner Institute, University of Oxford, Oxford, United Kingdom; 2 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 3 Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 4 Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 5 Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria)

‘Using pseudotypes for immunogenicity testing of universal influenza vaccines’
Nigel J. Temperton
(Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK)

‘Repeat vaccination reduces antibody affinity maturation irrespective of influenza vaccine platform in humans’
Surender Khurana1, Megan Hahn1, Elizabeth M. Coyle1, Lisa R. King1, Tsai-Lien Lin2, John Treanor3, Andrea Sant3 and Hana Golding1
(1 Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, Maryland, USA; 2 Division of Biostatistics, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, Maryland, USA; 3 University of Rochester Medical Center, Rochester, New York, USA)

‘The optimized fusion protein HA1-2-FliCΔD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice’
Li Song1,2,3,4, Dan Xiong1,2,3,4, Xilong Kang1,2,3,4, Yang Jiao1,2,3,4, Xiaohui Zhou1,2,3,4,5, Kaiyue Wu1,2,3,4, Yi Zhou1,2,3,4, Xinan Jiao1,2,3,4*, and Zhiming Pan1,2,3,4*
(1 Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, Jiangsu, China; 2 Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, Jiangsu, China; 3 Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, Ministry of Agriculture of China, Yangzhou University, Yangzhou, Jiangsu, China; 4 Joint International Research Laboratory of Agriculture and Agri-product Safety of the Ministry of Education, Yangzhou University, Yangzhou, Jiangsu, China; ePathobiology and Veterinary Science, College of Agriculture, Health and Natural Resources, University of Connecticut, Storrs, Connecticut, USA)

Lunch Break & Posters

SESSION 7:
VACCINES – I

Moderator: Yuri Vasiliev
(St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation)

‘Evaluation of exploratory cellular and humoral responses to FLU-v, a universal influenza peptide vaccine tested in a clinical phase IIb trial’
F. Oftung1, L.M. Næss1, D. B.-Bratlie1, I. Laake1, E. James2, G. Stoloff2 and O. Pleguezuelos2
(1 Infection Control and Environmental Health, Norwegian Institute of Public Health, (NIPH) Norway; 2 PepTcell Ltd (trading as SEEK), London, UK)

‘Next Generation H2 COBRA Hemagglutinin Vaccines Elicit Broadly Protective Antibodies Against H2Nx Influenza Viruses’
Z. Beau Reneer1, Parker J. Jamieson and Ted M. Ross1,2
(1 Center for Vaccines and Immunology, 2 Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA)

‘Intranasal immunization with Nanovax-rH5 vaccine (NanovaxrH5-NE01) induced Non-HAI antibodies that protected ferrets against a lethal heterologous clade of pandemic H5 flu challenge’
Ali Fattom
(Bluewillow Biologics. Ann Arbor, Michigan, USA)

‘Development of a broadly-protective M2e-based universal live attenuated influenza vaccine’
Irina Isakova-Sivak, Daria Mezhenskaya, Tatiana Kotomina, Victoria Matyushenko, Anastasia Evsina, Polina Prokopenko and Larisa Rudenko
(Institute of Experimental Medicine, St. Petersburg, Russia)

Tea Break & Posters

SESSION 8:
MODELS

Moderator: Shan Lu
(University of Massachusetts, Worcester, Massachusetts, USA)

‘The pig influenza challenge model’
Elma Tchilian
(The Pirbright Institute, Pirbright, Surrey, UK)

‘The intratracheal ferret challenge model to demonstrate effectiveness of Live attenuated, adjuvanted whole inactivated and split virus vaccines in preventing severe pneumonia induced by avian influenza’
Jørgen de Jonge1,Harry van Dijken1, Sanne Spijkers1, Justin Mouthaan1, Femke de Heij1, Rineke de Jong2, Paul Roholl3, Irina Isakova-Sivak4, Paulo Lee Ho5, Nicolas Colin6, Karen Smith-Korsholm7and Larisa Rudenko4
(1 Centre for Infectious Disease Control, RIVM, Bilthoven, The Netherlands; 2 Central Veterinary Institute of Wageningen UR, Lelystad, The Netherlands; 3 Microscope Consultancy, Weesp, The Netherlands; 4 Institute of Experimental Medicine, St. Petersburg, Russia: 5 Butantan, Sao Paulo, Brazil; 6 University of Lausanne (UNIL), Lausanne, France; 7 Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark)

‘In vitro assay and animal models for evaluation of Safety and Efficacy of next generation influenza vaccines and therapeutic antibodies’
Juanjie Tang, Laura Klenow, Hana Golding and Surender Khurana
(Division of Viral products, Center for Biologics Evaluation and Research, FDA, Silver Spring Maryland, USA)

SESSION 9:
VACCINES – II

Moderator: Othmar Engelhardt
(NIBSC, South Mimms, Potters Bar, UK)

‘Phase 3 results of quadrivalent nanoparticle influenza (Nanoflu) with Matrix-M™ adjuvant in adults 65 and older’
Vivek Shinde, Iksung Cho, Lou Fries, Jamie Fiske and Greg Glenn
(Novavax Inc.,Gaithersburg, Maryland, USA)

‘OVX836, a novel universal influenza a vaccine candidate: Short-term results of a phase i clinical trial in humans’
K, Withanage1, P.Van Damme1, A. LeVert2, S. Viviani2, P. Willems2 and F. Nicolas2
(1 University of Antwerp, Belgium; 2 Osivax, Lyon, France)

‘Development of T cell-targeted universal influenza vaccines’
Christopher S. Eickhoff1, Frances E. Terry2, Krystal A. Meza1, Lenny Moise2,3, Anne S. De Groot2,3and Daniel F. Hoft1,4
(1 Saint Louis University, Division of Infectious Diseases, Allergy and Immunology, Departments of Internal Medicine1 and Molecular Microbiology4, Saint Louis, Missouri, USA; 2 EpiVax, Inc., Providence, Rhode Island, USA; 3 University of Rhode Island; Institute for Immunology and Informatics, Providence, Rhode Island, USA)

‘Single-replication intranasal BM2SR vaccine provides cross-lineage protection against influenza B virus’
Pamuk Bilsel1, Mike Moser1, David Marshall1, Yasuko Hatta1 and Sally Sarawar2
(1 FluGen, Inc. Madison, Wisconsin, USA; 2 BRISC, San Diego, California, USA)

Coffee Break & Posters

SESSION 10:
PANEL DISCUSSION

Panel Discussion:
‘The elusive universal influenza vaccine: The way forward’

Moderator: To Be Confirmed

Lunch Break & Posters Breakdown

SESSION 11:
LATEBREAKER SESSION

Moderator: Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘Harnessing the clec9a-targeting strategy to boost the immunogenicity of the universal flu antigen vaccine candidate M2e’Ranmali Kavishna1, Mireille Lahoud2 and Sylvie Alonso1
(1 Department of Microbiology & Immunology, Yong Loo Lin School of Medicine; and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore; 2 Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia)

‘Systemic and respiratory T-cells induced by seasonal H1N1 influenza protect against pandemic H2N2 in ferrets’K. van de Ven, H. van Dijken, F. de Heij and J. de Jonge
(Centre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands)

‘Universal vector influenza vaccines: Pre-clinical research’Igor Krasilnikov1, Ludmila Tzibalova2 and Marina Stukova2
(1 Saint-Petersburg Institute of Vaccines and Sera, FMBA Russia, St.- Petersburg, Russia; 2Smorodintsev Research Institute of Influenza, St.-Petersburg, Russia)

‘SEC meets TRPS: Automated isolation and high-precision analysis of extracellular vesicles and viruses’Camille Roesch1, Anoop K. Pal2, Shayne Harrel3, Robert Vogel2 and Murray Broom2
(1 Izon Science Europe Ltd, Lyon, France; 2 Izon Science Ltd, Medford, Massachusetts, USA; 3 Izon Science Ltd, Christchurch, New Zealand)

‘Nano-flow cytometry: A platform for comprehensive virus and extracellular vesicle analysis’Dimitri Aubert
(NanoFCM, Medicity, Nottingham, UK)

Latebreaker abstracts for oral and poster presentation at UIV 2022 are called for. Please see the Participation page for details.

‘Evaluation of vaccine efficacy against Moroccan strain of LPAI H9N2 in experimental models in broiler chicken’
Yassmina Bidoudan
(Hassan II Veterinary and Agronomy Institute, Morocco)

‘Evaluation of exploratory cellular and humoral responses to FLU-v, a universal influenza peptide vaccine tested in a clinical phase IIb trial’
F. Oftung1, L.M. Næss1, D.B.-Bratlie1, I. Laake1, E. James2, G. Stoloff2 and O. Pleguezuelos2
(1 Infection Control and Environmental Health, Norwegian Institute of Public Health (NIPH), Norway; 2 PepTcell Ltd (trading as SEEK), London, UK)

This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.